ZMB Member Sebastian Bauer
ZMB Member
Sebastian Bauer
Next ZMB-Member
Prof. Dr. Sebastian Bauer
West German Cancer Center (WTZ)
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 2112
- Website
- Press Releases
- Selected Publications
- Publication Metrics
-

- ZMB Research Program
Oncology
Research Overview
- Analysis of oncogenetic signalling pathways in soft-tissue sarcoma (esp. GIST)
- Evaluation of purposive, small molecular inhibitors of tyrosine kinases in soft-tissue sarcoma
- Development of soft-tissue sarcoma models (cell lines and Xenografts)
- Evaluation of preclinical diagnostic techniques/methods (in vitro/in vivo) for GIST and other soft-tissue sarcoma
Selected Publications
-
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRAIn: Nature Communications, Vol. 15, 2024, Nr. 1, 63DOI (Open Access)
-
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors : A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesIn: Clinical Cancer Research, Vol. 30, 2024, Nr. 4, pp. 719 – 728
-
Correction to: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications, Vol. 15, 2024, Nr. 1, 2364DOI (Open Access)
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor : ctDNA biomarker analysis of the phase 3 INTRIGUE trialIn: Nature Medicine, Vol. 30, 2024, Nr. 2, pp. 498 – 506DOI (Open Access)
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized TrialIn: Clinical Cancer Research, Vol. 29, 2023, Nr. 17, pp. 3313 – 3319DOI (Open Access)
-
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications, Vol. 14, 2023, Nr. 1, 4632DOI (Open Access)
-
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 TrialIn: Clinical Cancer Research, Vol. 29, 2023, Nr. 24, pp. 5057 – 5068
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective StudyIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 8, pp. 1672 – 1679DOI (Open Access)
-
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma : Results from a Proof-of-Concept, Phase Ib StudyIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 6, pp. 1087 – 1097DOI (Open Access)
-
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 5, pp. 870 – 881DOI (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 19, pp. 4346 – 4353DOI (Open Access)
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudyIn: Clinical Cancer Research, Vol. 27, 2021, Nr. 23, pp. 6333 – 6342DOI, Online Full Text (Open Access)
-
Defective homologous recombination DNA repair as therapeutic target in advanced chordomaIn: Nature Communications, Vol. 10, 2019, Nr. 1, pp. 1635DOI (Open Access)
-
Integrative genomic and transcriptomic analysis of leiomyosarcomaIn: Nature Communications, Vol. 9, 2018, Nr. 1, pp. 144DOI (Open Access)
-
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationIn: Nature Communications, Vol. 8, 2017, 14674DOI (Open Access)
-
Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumorsIn: Clinical Cancer Research, Vol. 23, 2017, Nr. 3, pp. 845 – 856
-
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsIn: Clinical Cancer Research, Vol. 20, 2014, Nr. 22, pp. 5745 – 5755
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research, Vol. 73, 2013, Nr. 12, pp. 3661 – 3670
-
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GISTIn: Cancer Research, Vol. 73, 2013, Nr. Suppl. 8
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research, Vol. 70, 2010, Nr. 1, pp. 150 – 159
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research, Vol. 69, 2009, Nr. 17, pp. 6941 – 6950DOI (Open Access)
